TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lobar-only treatments~* Patients with biopsy or radiographically proven hepatocellular carcinoma who are not candidates for transplant, surgical resection or ablative therapy~* Patients 18 years of age and older~* Patients who are able to provide written informed consent~Exclusion Criteria:~* Patients with Barcelona-Clinic Liver Cancer (BCLC) Stage C disease,~* Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3,~* Patients who are unable to tolerate Y-90,~* Patients with arterial anatomy unsuitable to place Surefire catheter,~* Patients with uncorrectable coagulopathy,~* Patients with platelets less than 50 (uncorrectable),~* Bilirubin \>3 mg/dl,~* AST or ALT\>5x upper limit of normal,~* Patients who are unable to tolerate angiography,~* Patients with \< 3 months to live,~* Patients who meet the standard Y-90 exclusion criteria according to package insert~* Female patients who are pregnant~* Patients under the age of 18~* Patients who are unable to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surefire® Infusion System (Type: EXPERIMENTAL): Patients randomized to the Surefire® Infusion System treatment arm will undergo Y-90 glass microsphere embolization with a Surefire catheter.
- Standard End-hole catheter (Type: ACTIVE_COMPARATOR): Patients randomized to the standard end-hole catheter treatment arm will undergo Y-90 glass microsphere embolization with a standard end-hole catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be between the ages of 18-90 years of age.~2. Patients must be able to understand the nature of this study, give written informed consent prior to study entry, and comply with study requirements.~3. Patients must have a corneal ulcer greater than 2mm but less than 6mm in size.~4. Patients must have corneal ulcer present in only one eye.~5. Patients must agree not to wear contact lenses while on study.~Exclusion Criteria:~1. Patients with multifocal ulcers.~2. Signs of any other viral or fungal infection.~3. Treatment with antibiotics within 14 days of study entry.~4. Treatment with systemic or topical ocular antiviral agents or systemic or topical steroids or topical ocular nonsteroidal anti-inflammatory drugs (NSAIDS) during the prior 14-day period.~5. Known hypersensitivity or allergy to steroids (Loteprednol etabonate) or to any of the ingredients in the three study drugs (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%).~6. Contact lens only with no spectacles available.~7. Ocular surgery (including laser surgery) in either eye within 6 weeks prior to entry into this study.~8. Participation in any investigational study within the past 30 days.~9. Pregnant women, minors, or those not able to consent for themselves.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Besivance 0.6% Ophthalmic Suspension (Type: ACTIVE_COMPARATOR): A topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis.
- Zymaxid 0.5% Ophthalmic Solution (Type: ACTIVE_COMPARATOR): A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
- Vigamox 0.5% Ophthalmic Solution (Type: ACTIVE_COMPARATOR): A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of FeNO During and Following Acute COPD Exacerbation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 40 years and above, inclusive~* Sex: Males and Females~* Smoking History: ≥20 pack years.~* COPD Defined as an FEV1/ FVC or FEV1/SVC ratio \<70% predicted.~* AECOPD defined as a clinically significant worsening of COPD symptoms requiring treatment with antibiotics and/or systemic steroids and/or hospitalization for same.~Exclusion Criteria:~* Use of Systemic Corticosteroids for more than 48 hours prior to Visit 1.~* AECOPD requiring mechanical ventilation~* Study Participation Outside of This Protocol: Patients currently enrolled in studies of Investigational or non-Investigational Drugs or Medical Devices and/or who participated in these studies within 30 days prior to this study are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All participants must have a documented diagnosis of relapse/refractory Multiple Myeloma and have measurable disease as defined per IMWG criteria.~* All participants must have received at least 3 prior lines of MM therapy with IMiD, PI and Anti-CD-38, and progressed on their last therapy (prior BCMA targeted therapy allowed).~* All participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1or 2.~* All participants must have adequate organ function.~* Females of childbearing potential (FCBP) or male participant must agree to follow contraception requirements.~Exclusion Criteria:~* All participants with non-secretory MM~* All participants with known auto-immune disease~* All participants with history of life-threatening toxicity related to prior immune therapy.~* All participants with active graft versus host disease after allogeneic stem cell transplantation.~* All participants with active, unstable cardiovascular function.~* All participants with active infection requiring systemic therapy.~* All participants with hypersensitivity to any of the treatments.~* All participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Participants will receive EOS884448 (Type: EXPERIMENTAL): EOS884448 will be administered
- B: Participants will receive EOS884448 and iberdomide (Type: EXPERIMENTAL): EOS884448 and iberdomide will be administered
- C: Participants will receive EOS884448, iberdomide and dexamethasone (Type: EXPERIMENTAL): EOS884448, iberdomide and dexamethasone will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Adapted Physical Activity for Breast Cancer HER2 Positive Patient

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women \> 18 years old~* Patient with HER2 (Human Epidermal growth factor Receptor 2) positive breast cancer histologically proven, eligible for neoadjuvant chemotherapy and targeted therapy against HER-2~* Affiliation to the French social security scheme~* Patient who signed the participation consent before entering the trial~* Medical fitness certificate for sport~Exclusion Criteria:~* Diagnosis of a second malignancy in the past 5 years, with the exception of a basal cell skin cancer~* Metastatic cancer~* Karnofsky index ≤ 90%~* Men~* Pregnant women~* Significant psychiatric or neurological abnormality~* Patient deprived of liberty by a court or administrative~* Contraindication for physical activity~* Patient unable to complete questionnaires (language barrier)~* Participation in a clinical trial with the same objective

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interventional (Type: EXPERIMENTAL): Home-Based Adapted Physical Activity intervention during neoadjuvant chemotherapy :~150 minutes per week of aerobic and muscle strengthening exercises during 18 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Protein Oral Nutritional Support With Special Nutrients in Patients With Type 2 Diabetes and Foot Ulcer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes with newly diagnosed foot ulcer~* accept study participation~Exclusion Criteria:~* HbA1c \>90 mmol/L~* cognitive challenges, fx dementia~* history with known alcohol or drug abuse~* allergy to milk or soya~* home less~* critical ischemia, distal blood pressure \<0.30~* EGFR \< 30~* dialysis or planned dialysis or patients with terminal kidney insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Cubitan (Type: EXPERIMENTAL): 2 x oral nutritional supplement daily
- Usual care (Type: NO_INTERVENTION): usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~In order to be eligible to participate in this study, an individual must meet all of the following criteria:~1. Stated willingness to comply with all study procedures and availability for the duration of the study~2. Male or female, aged 18 or older.~3. History of positive PCR or positive IgG for SARS-CoV-2 cases and if known history of COVID-19 infection, at least 30 days passed since a positive PCR for SARS-COV-2 and have been asymptomatic for at least 10 days.~4. Willing to undergo study required testing and blood draw.~5. Willing to have blood samples stored for future research.~EXCLUSION CRITERIA:~An individual who meets any of the following criteria will be excluded from participation in this study:~1. Current symptoms consistent with COVID-19 infection.~2. Any condition or event that, in the PI s opinion, may substantially increase the risk associated with study participation or compromise the study's scientific objectives. Conditions that exclude a subject are considered to be unlikely, but an example would include having an acute respiratory infection or recent exposure that would make it unsafe to perform study procedures or obtain blood samples.~3. Pregnant and decisionally impaired individuals will be excluded from participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Affected Participants (Type: None): Participants previously diagnosed with COVID-19.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Physical Exercise And Cognitive Engagement Outcomes for Mild Neurocognitive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
For the patients diagnosed with MCI:~Inclusion Criteria:~1. Written informed consent for participation. Patient also needs to sign a legally authorized representative (LAR) addendum should MCI patient become incapacitated~2. A diagnosis of amnestic MCI (single domain or multi-domain)~3. A Clinical Dementia Rating scale score of 0 or 0.5~4. At least 50.~5. Either not taking or stable on nootropic(s) and/or pain medication for at least 3 months.~6. Fluent in English.~7. A score of at least 25 on the Telephone Interview for Cognitive Status for Memory.~Exclusion Criteria:~1. MRI contraindications (e.g., ferrous metal in the body, claustrophobia, pregnancy)~2. Physical impairments, language comprehension deficits, or significant hearing disturbances that would limit ability to perform tasks or participation in the intervention.~For the care partners:~Inclusion Criteria:~1. Written informed consent for participation.~2. At least 21 years of age.~3. A score of at least 32 on the Telephone Interview for Cognitive Status for Memory.~4. Partner has at least twice-weekly contact with the participant.~Exclusion Criteria:~1. Physical impairments, language comprehension deficits, or significant hearing disturbances that would limit ability to perform tasks or participation in the intervention.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Computerized brain fitness training (Type: EXPERIMENTAL): Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Calendar Training and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue the computerized brain fitness for another 24 weeks.Participants are encouraged to do at least two hours per week.
- Yoga (Type: EXPERIMENTAL): Will receive a 10 day intervention program (over 2 weeks) consisting of Yoga, Calendar Training, and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue yoga for 24 weeks. Participants assigned to the yoga intervention will continue to meet with their group and their yoga instructor for one hour per week and will be expected to do at least an additional hour of yoga by themselves every week.
- Wellness Education (Type: ACTIVE_COMPARATOR): Will receive a 10 day intervention program (over 2 weeks) consisting of Wellness Education, Calendar Training and Support Group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Brief Motivational Enhancement Therapy for Concurrent Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 16-65~* DSM-IV Diagnoses of a psychotic disorder and a substance use disorder (tobacco, alcohol and/or drug)~* Fluent English speaker~* Capable of giving written informed consent~Exclusion Criteria:~* Any medical or neuropsychiatric condition, illness or disorder (e.g. unstable angina, severe dementia) that could compromise attendance to outpatient appointments.~* Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brief Motivational Enhancement Therapy (Type: EXPERIMENTAL): None
- treatment as usual (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Investigating Four Nasal CPAP Systems in the Management of Apnea of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* gestational age at birth \< 34 weeks~* postconceptional age and body weight at study ≤38 week and \>1000 g~* requirement for N-CPAP to treat AOP as judged by the attending neonatologist~Exclusion Criteria:~* congenital or chromosomal abnormalities~* acute infections~* intraventricular hemorrhage~* additional inspired oxygen to maintain pulse oximeter saturation SpO2 \>92%~* patent ductus arteriosus

- Gender: ALL
- Minimum Age: None
- Maximum Age: 14 Weeks
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AZD8075 Single Ascending Dose Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed, written and dated informed consent prior to any study specific procedures.~* Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg.~* Be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for \>6 months prior to study start.~Exclusion Criteria:~* Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the result of the study, or the subject's ability to participate~* Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs (vital signs (ie, supine BP and pulse) or ECG at baseline, which, in the opinion of the investigator, may put the subject at risk.~* Participation in another investigational drug study within 3 months before Visit 2 or participation in a method development study (no drug) 1 month prior to Visit 2

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Ketamine and Morphine in the Treatment of Acute Fracture Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible Long bone fractures. This will include:~* Humerus~* Tibia~* Fibula~* Femur~* Radius~* Ulna~Exclusion Criteria:~* Injuries older than 24 hours~* Avulsion fractures~* History of substance abuse~* History of chronic opioid dependence~* Pregnancy~* Demonstrates signs of intoxication~* Allergic to ketamine or opioids~* Patients unable to consent~* Hemodynamically unstable (SBP \>180mmHg or \<100mgHg, HR \>130bpm, Respiratory rate \<10, oxygen saturations \<90%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
- Morphine (Type: EXPERIMENTAL): Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent vestibulopathy patient with symptoms more than 3 months of recurrent vertigo~* Visual analogue scale (VAS) score between 4 to 8~Exclusion Criteria:~* Showing signs of central lesion in MRI or neurologic exams~* central nystagmus or loss of consciousness with vertigo~* cerebellar symptoms such as ataxia, dysarthria, gait disturbance~* Diagnosed as peripheral vertigo such as benign paroxysmal positional vertigo, Meniere's disease, migrainous vertigo in recent 3 months~* Bilateral vestibular dysfunction~* Vestibular neuronitis symptom appeared in recent 6 months~* Chronic liver disease (ALT\>100 or AST\>100) or chronic kidney disease (Creatinine \> 3.0 mg)~* Blood Hemoglobin \< 10mg/dl (in male) or \< 8 mg/dl (in female)~* Contraindication for testing drug (ex. Pregnancy or breast feeding etc.)~* Taking antiepileptics such as phenobarbital, phenytoin, carbamazepine or rifampin in recent 2 weeks~* Taking cilostazol, gingko biloba for other disease~* Allergy/hypersensitivity to Renexin~* Severe drug toxicity when taking Renexin previously

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Renexin (Type: ACTIVE_COMPARATOR): Renexin 1T bid for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1T bid for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues